The U.S Food and Drug Administration (USFDA) has issued Establishment Inspection Report (EIR) to Shilpa Medicare’s Bio Analytical Laboratory, Unit 7, Nacharam, Hyderabad. The facility is classified as ‘No Action Indicated’ (NAI).
Bio Analytical Laboratory, Shilpa Medicare, Unit 7, Nacharam, Hyderabad, India was inspected by USFDA from February 26, 2024 to March 01, 2024. The inspection was concluded with zero 483 observations and no discussion items.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
